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Atopic dermatitis (AD) is a complex immunemediated, chronic inflammatory skin condition characterized by intense pruritus, [1] [2] [3] with a prevalence of at least 3% in the US general population. 4, 5 Presenting either as adultonset disease or beginning in childhood/infancy and persisting or recurring in adulthood, 4, 6, 7 adult AD has a prevalence that has been estimated as being on the order of 2% to 10%, with moderate or severe disease prevalent in 34% to 46% of adult patients with AD. 8, 9 The substantial public health impact of AD in terms of both populationlevel health loss and attendant disability was established by the 2010 Global Burden of Skin Disease project and more recently validated by the Cochrane Skin Group in 2014. 10, 11 Whereas skin conditions in general were the fourth leading cause of nonfatal disease burden across all chronic diseases, AD was particularly implicated as causing the greatest population-level disability within the skin disease classification alone. 10 To inform further national and global health debate on prioritizing skin diseases on health care agendas, 11 further broad and representative studies of AD are required, particularly from a humanistic perspective.
The objective of this study was to establish the humanistic burden of AD in the US adult general population in terms of mood and sleep disorders, effects on health-related quality of life (HRQoL), and impairment of work productivity (including lost wages) and everyday activities and also to assess how variations in AD severity affect this burden. Further examination of these outcomes in patients with psoriasis was conducted to provide contextualization against another common chronic inflammatory skin disease that is widely recognized to be associated with high prevalence and significant patient impairment. 5, 10, [12] [13] [14] 
METHODS

Study design
This cross-sectional study investigated the burden of adult AD in the United States on the basis of the 2013 US National Health and Wellness Survey (NHWS), a large, Internet-based, general population survey fielded to randomly sampled patient segments of the population 18 years and older (Kantar Health, New York, NY). The survey covered patient diagnosis and health profiles, demographics, attitudes and approaches to health care, patient-reported outcomes, and health care resource utilization. The NHWS sample is drawn from an Internet panel maintained by Lightspeed Research (Warren Township, NJ). Panel members are recruited through opt-in e-mails, partner panels, e-newsletter campaigns, banner placements, and affiliate networks, with registration via unique e-mail addresses and passwords, after completion of an in-depth demographic profile.
Subjects
The survey sample for AD was identified on the basis of the following 2 questions, for which inclusion in the AD sample required ''yes'' to be chosen for both questions: ''Which of the following conditions (dermatitis/eczema/AD) have you experienced in the past 12 months?'' If ''yes'' was chosen for AD, the following question was asked: ''Has your AD been diagnosed by a physician?'' Those who did not report any of the conditions were eligible to be placed into the non-AD control group before a propensity matching process.
Subjects with AD were further categorized into 2 severity groups (mild vs moderate or severe) on the basis of self-reported disease severity in response to the question, ''How severe is your AD? Mild/ moderate/severe.'' Additionally, subjects with psoriasis were selected and similarly categorized on the basis of whether respondents had ever experienced psoriasis (and if so, whether their symptoms had ever been diagnosed as psoriasis by a physician) and their self-reported disease severity. Respondents who reported a diagnosis of both conditions were excluded from the analysis. Severity for psoriasis was reported on the basis of the following question: ''According to the National Psoriasis Foundation, the palm of the hand equals 1
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percent of the skin. Thinking about this, please estimate the percent of your body surface your psoriasis currently affects: less than 3% body coverage (mild); 3% to 10% body coverage (moderate); or more than 10% body coverage (severe).''
Outcomes
The burden of AD was established on the basis of following patient-reported outcomes:
Mental health. Self-reported diagnoses of anxiety, depression, and/or sleep disorders were based on a subject's affirmative response to separate questions for each of the disorders, such as ''Have you experienced anxiety/depression/sleep disorders in the past 12 months?'' If subjects reported presence of the disorder, they were also asked to confirm whether a physician had provided its diagnosis.
HRQoL during the past 4 weeks. This was assessed by using the 36-Item Short Form Health Survey (SF-36v2) Mental Component Summary (MCS) and Physical Component Summary (PCS) scores 15 and the Short Form 6-Dimension (SF-6D) utility score, a preference-based single-index measure for health based on SF-36 data and weighted according to general population values for health; scores are estimated on a 0 to 1 scale, with higher scores indicating better health status. 16 Work productivity and activity impairment. 17, 18 The Work Productivity and Activity Impairment (WPAI) questionnaire characterized work productivity and everyday activity impairment across 4 domains, percent absenteeism (percentage of work time missed during the past 7 days on account of the health problem); percent presenteeism (percentage of impairment due to the health problem while working during the past 7 days); percent overall work impairment (percentage of overall work impairment due to the health problem [absenteeism 1 presenteeism]); and percent activity impairment (percentage of activity impairment due to the health problem).
Indirect costs of AD. These are based on lost wages due to reduced productivity reported on the WPAI questionnaire. Costs for each respondent were calculated by using estimated salaries based on data from the US Bureau of Labor Statistics 19 stratified according to age and sex (Supplemental Table I ; available at http://www.jaad.org). The mean number of hours of absenteeism and hours of presenteeism were multiplied by the hourly salary rates to arrive at total lost wages.
Statistical methods
Bivariate analyses of demographics and outcomes were conducted between subjects with AD and non-AD controls and between subjects with AD and those with psoriasis. Chi-square and t tests were used to determine significant differences for categorical and continuous variables and as the basis for identifying covariates for multivariable models, with the AD and control groups propensity-matched (ie, AD vs no AD and AD vs psoriasis) to correct for any sampling bias. 20 Adults who experienced symptoms in the past 12 months and self-reported a diagnosis of AD were propensity scoreematched (1:2) to non-AD controls on the basis of propensity scores obtained from logistic regression models incorporating age, sex, ethnicity, education, income, insurance status, alcohol consumption, and exercise behavior.
Separately, adults with a self-reported diagnosis of AD were propensity scoreematched (1:1) to adults who self-reported a diagnosis of psoriasis. Differences on health outcomes were examined by using odds ratios (ORs), t tests, and analysis of variance to establish burden in subjects with AD versus matched non-AD controls and in subjects with AD versus matched subjects with psoriasis, and also to demonstrate the incremental burden associated with higher AD severity.
RESULTS
AD versus non-AD and AD versus psoriasis
Demographic and clinical characteristics. Overall, 352 subjects with a diagnosis of AD and 70,830 subjects not experiencing AD, eczema, or dermatitis (ie, the non-AD subjects) were selected. From the AD sample, 349 subjects with AD were matched (1:2) with 698 non-AD controls and 260 subjects with AD were matched (1:1) with 260 psoriasis controls. Demographics and baseline characteristics were comparable between the matched AD and control groups: the mean age of the combined matched AD and non-AD control sample was 46.1 years; 68.3% were women, and 66.8% were non-Hispanic whites (Supplemental Table II ; available at http://www.jaad.org).
Examination of self-reported disease severity before propensity matching indicated that greater (Fig 1, B and C ) .
HRQoL. Significantly reduced HRQoL on both mental and physical domains was reported by subjects with AD relative to matched non-AD controls (Supplemental Table III ; available at http://www.jaad.org). The mean MCS score was 44.5 for subjects with AD versus 48.0 for non-AD controls (P \.001), and the mean PCS score was 47.6 for subjects with AD versus 49.5 for non-AD controls (P = .004) (estimated on a scale of 0 to 100 for both components, with higher scores indicating better health status). Mean SF-6D health utility scores were also significantly lower for subjects with AD than for non-AD controls (0.67 vs 0.72, respectively, P\.001) (estimated on a scale of 0 to 1, with higher scores indicating better health status). Compared with psoriasis, AD had a similar impact on HRQoL.
Productivity and indirect costs. Work productivity and activities were similarly affected by the presence of AD. Compared with employed matched non-AD controls, employed subjects with AD (n = 195) reported higher absenteeism (9.9% vs 3.6% [P \ .001]), presenteeism (21.1% vs 16.1% [P = .027]), and overall work impairment (25.6% vs 18.1% [P = .004]), respectively (Fig 2, A) . The mean annual indirect costs for employed subjects, taking into account the effect of work absenteeism and presenteeism, were approximately $2400 higher for subjects with AD versus for non-AD controls ($8907 vs $6517, respectively [P = .024]). For daily activities in all subjects, mean percentage impairment was also significantly higher for the AD group than for the matched non-AD controls (33.6% vs 25.2% [P \.001]) (Fig 2, A) .
AD and psoriasis had a similar impact on productivity outcomes and indirect costs; although absenteeism and activity impairment were numerically higher (9.3% vs 6.1% and 32.4% vs 31.9%, respectively) in subjects with AD than in subjects with psoriasis, the differences did not reach statistical significance (Fig 2, B) .
Mild versus moderate or severe AD
There was a numerically higher, but not statistically significantly greater, burden reported by patients with moderate or severe AD than by those with mild AD in terms of mood or sleep disorders, mental health domain of SF-36v2 (MCS), SF-6D health utility scores, absenteeism, presenteeism, and overall work impairment. The physical health domain of the SF-36v2 (PCS) showed significantly lower HRQoL in patients with moderate or severe AD than in patients with mild AD (P \.001). 
DISCUSSION
This real-world survey of adults with and without a self-reported diagnosis of AD has revealed the extent of the humanistic burden that is associated with AD. Approximately one-third of the patients with AD reported mood and sleep disorders, which is almost twice the rate reported by non-AD controls. Moreover, AD was associated with significantly poorer HRQoL when compared with that of the matched non-AD controls.
Previous studies on several chronic health conditions have suggested that differences of 2.5 to 5 points on the SF-36 MCS and PCS scores are clinically meaningful. [21] [22] [23] [24] Although further validation is required in AD, the 3.5-point difference between the AD and non-AD groups on the SF-36 MCS is likely to be clinically significant and reveals the ''hidden'' mental burden of AD manifesting via reduced vitality, social functioning, or emotional well-being.
For the overall AD group compared with the matched non-AD control group, increased impairments in work and daily activities and magnitude of lost wages were significant. This outcome underscores not only the impact of this disease at the personal level but also its potential burden at the societal level, which can be inferred if the 6.3% incremental absenteeism rate is projected on the segment of the US working population with AD, indicating the extent of productivity losses associated with AD in the US workforce.
Within AD, patients with moderate or severe disease generally report significantly greater disease burden than do patients with mild AD, including in terms of itch, pain, sleep disturbance, anxiety, depression, and HRQoL. 25, 26 The nonsignificant differences between severity levels in this study were likely due to lack of adequate power on account of small sample size. In addition, less than one-fifth of the patients in the moderate or severe group selfreported their disease as severe; thus, the burden reported for these patients reflects outcomes for patients with moderate AD much more so than for patients with severe disease. Finally, the discordance between patient and physician global assessment of disease severity 27 highlights the need for objective assessment of AD severity in patient self-reported surveys through validated instruments such as the Patient-Oriented Severity Scoring of Atopic Dermatitis or the Patient Oriented Eczema Measure.
Against a benchmark of psoriasis, self-reported mood and sleep disorders and impairments in HRQoL, work productivity, and activities of daily living were similar for AD. It is notable, however, that a higher proportion of subjects with AD reported moderate or severe disease compared with subjects with psoriasis, potentially suggesting a relatively greater unmet clinical need among subjects with AD.
A few methodologic limitations must be noted. Diagnoses and other clinical variables were not verifiable by patient medical charts owing to the self-reported nature of the data; hence, the validity of the study may be reduced, as self-reported data are subject to recall bias. Furthermore, as the data were cross-sectional, establishing causality was not possible. Although a number of respondent characteristics were adjusted for, there may be additional variables that were not adjusted for and that may have confounded the results. Although the NHWS was designed to be representative of the general US adult population, it is possible that the AD and psoriasis subpopulations may have been selectively underrepresented because of age and/or technology-related limitations, so the sample is likely to favor younger, healthier adults.
However, the findings of this study are in agreement with the results of an initial characterization of the patient-reported burden of AD in the US general population using the NHWS database. 28 Our study not only confirms these previous findings but also reveals the magnitude of outcomes against a benchmark of psoriasis, which is another inflammatory skin disease with a similar epidemiologic burden, 1 and a possibly underreported disability burden given the associated and debilitating manifestations of the disease not considered in published reports of disability. 10, 11 In totality, these implications are alarming and underscore the public health concerns of AD reported in global epidemiologic studies.
10,11
CONCLUSIONS
This study demonstrates the substantial and important impact of AD on mood and sleep, the mental and physical dimensions of HRQoL, and work productivity and everyday activity impairment in adults with AD. Moreover, disease burden in AD is comparable with that of psoriasis and suggests the need for more effective management of this condition.
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